8-K: Arcturus Therapeutics Announces Q1 2025 Financial Results and Pipeline Prioritization, Extending Cash Runway into 2028

Arcturus Therapeutics reports Q1 2025 financial results, highlights pipeline progress, and announces an extended cash runway into 2028 through strategic prioritization.

Summary

• Arcturus Therapeutics announced its Q1 2025 financial results and provided a corporate update.
• Revenues for the quarter were $29.4 million, compared to $38.0 million in the same period in 2024, primarily due to lower milestone revenues from the CSL collaboration as KOSTAIVE transitions to the commercial phase.
• Total operating expenses for the quarter were $46.2 million, down from $68.4 million in Q1 2024.
• Research and development expenses decreased to $34.9 million from $53.6 million year-over-year, driven by lower manufacturing costs for KOSTAIVE, LUNAR-FLU, and BARDA programs.
• General and administrative expenses decreased to $11.3 million from $14.9 million year-over-year, mainly due to reduced share-based compensation costs.
• The company reported a net loss of $14.1 million, or ($0.52) per diluted share, compared to a net loss of $26.8 million, or ($1.00) per diluted share in Q1 2024.
• Cash, cash equivalents, and restricted cash totaled $273.8 million as of March 31, 2025.
• The company's cash runway is expected to extend into 2028 due to the reallocation of resources to the therapeutics pipeline.
• Interim data from the ARCT-032 Phase 2 CF study is expected in mid-2025, and enrollment is expected to complete by year-end.
• Interim data from the ARCT-810 Phase 2 OTC deficiency study is expected in Q2 2025.
• The company received the initial milestone payment from CSL related to the EU approval of KOSTAIVE.
• KOSTAIVE regulatory guidance includes an MAA filing in the United Kingdom anticipated in Q2 2025, followed by a U.S. BLA filing expected in Q3 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue is down, operating expenses are also down, and the cash runway has been extended. The company is making progress with its pipeline programs, but there are still risks and uncertainties.

Positives

• The company's cash runway has been extended into 2028, providing financial stability.
• Operating expenses have decreased, indicating improved cost management.
• The net loss has decreased, showing progress towards profitability.
• The company received a milestone payment from CSL for KOSTAIVE's EU approval.
• ARCT-2304, a vaccine candidate for Pandemic Influenza A Virus H5N1, received U.S. FDA Fast Track Designation.
• KOSTAIVE has demonstrated a favorable safety profile in a large clinical study.

Negatives

• Revenues decreased compared to the same period last year, primarily due to lower milestone revenues from the CSL collaboration.
• The company reported a net loss for the quarter, although it was smaller than the loss in the same period last year.

Risks

• The company's future success depends on the success of its pipeline programs, which are subject to clinical and regulatory risks.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's financial performance is dependent on continued collaboration and milestone payments from partners like CSL Seqirus.

Future Outlook

Arcturus expects to provide Phase 2 interim data for ARCT-032 (CF) in mid-2025 and complete enrollment by year-end. The company also expects Phase 2 interim data for ARCT-810 (OTC) in Q2 2025. KOSTAIVE regulatory filings are anticipated in the UK (Q2 2025) and the US (Q3 2025). The cash runway is expected to extend into 2028.

Management Comments

• 'We are delighted with enrollment in our cystic fibrosis (CF) program, and the company is working diligently to provide meaningful Phase 2 interim data mid-year,' said Joseph Payne, President & CEO of Arcturus Therapeutics.
• 'We are encouraged by the clinical progress of our CF and OTC programs, and given the current market conditions, we made a strategic decision to streamline resources to focus on our mRNA therapeutics pipeline.'
• 'I am happy to report we have received the initial European Union (EU) approval milestone payment from our partnership with CSL,' said Andy Sassine, Chief Financial Officer of Arcturus.
• 'I am also pleased to report that the cash runway now extends into 2028 with the re-allocation of resources to our therapeutics pipeline.'

Industry Context

Arcturus is operating in the competitive mRNA therapeutics and vaccines space, alongside companies like Moderna and BioNTech. The company's focus on rare diseases and infectious disease vaccines, along with its proprietary LUNAR delivery technology and STARR mRNA technology, positions it to compete in this market. The collaboration with CSL Seqirus for mRNA vaccines is a significant partnership in the industry.

Comparison to Industry Standards

• Arcturus' cash runway extending into 2028 provides a competitive advantage compared to smaller biotech companies that often face near-term funding concerns.
• The company's progress with KOSTAIVE, the first self-amplifying mRNA COVID vaccine to be approved, demonstrates its innovation in the mRNA vaccine space, similar to Moderna and BioNTech's achievements.
• The focus on rare diseases like cystic fibrosis and OTC deficiency aligns with the industry trend of developing targeted therapies for unmet medical needs, similar to companies like Vertex Pharmaceuticals in cystic fibrosis.
• Arcturus' collaboration with CSL Seqirus mirrors the partnerships seen between other biotech companies and larger pharmaceutical firms to develop and commercialize mRNA vaccines, such as the Pfizer-BioNTech collaboration.

Stakeholder Impact

• Shareholders: The extended cash runway and pipeline progress are positive, but decreased revenue may be a concern.
• Employees: Streamlining resources may lead to some job losses, but the focus on the mRNA therapeutics pipeline could create new opportunities.
• Patients: Progress in CF and OTC programs could lead to new treatment options.
• Partners: Continued collaboration with CSL Seqirus is important for the company's success.

Next Steps

• Provide Phase 2 interim data from the ARCT-032 CF study in mid-2025.
• Complete enrollment in the ARCT-032 (CF) Phase 2 study by year-end.
• Provide Phase 2 interim data from the ARCT-810 OTC deficiency study in Q2 2025.
• Complete KOSTAIVE regulatory filings in the United Kingdom (Q2 2025) and the United States (Q3 2025).
• Provide interim Phase 1 study data for Pandemic Influenza A virus H5N1 in H2 2025.

Key Dates

Keywords

Arcturus Therapeutics, mRNA, KOSTAIVE, Clinical Trials, Financial Results, Pipeline, ARCT-032, ARCT-810, CSL Seqirus, Vaccine